Burden of Responding to Patent Expiries for Core Products
First written in FY2017-Q2. 11 of 17 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2017: 4 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Other".
- FY2026-H1Decline in long-listed product sales due to designated medical treatmentAnnual report
「Among long-listed products, sales of Mucodyne, an airway mucus regulator and mucosal normalizer, increased, while sales of Kipres, a treatment for bronchial asthma and allergic rhinitis, declined due to the impact of selected medical care for long-listed products and other factors.」
For long-listed products following patent expiration, the company newly identifies selected medical care for long-listed products and other factors as causes of the decline in Kipres sales. - FY2024-Q3RestatedAnnual report
「On the other hand, sales of long-listed products such as Pentasa, a treatment for ulcerative colitis and Crohn's disease, declined.」
The company continues to report declines in sales of existing products, including long-listed products following patent expirations. - FY2024-Q1RestatedAnnual report
「On the other hand, sales of long-listed products such as Kipres, a treatment for bronchial asthma and allergic rhinitis, and Pentasa, a treatment for ulcerative colitis and Crohn's disease, declined.」
The company continues to report declines in sales of core and long-listed products such as Kipres and Pentasa following patent expirations. - FY2023-Q1RestatedAnnual report
「On the other hand, sales of long-listed products such as Kipres, a treatment for bronchial asthma and allergic rhinitis, and Pentasa, a treatment for ulcerative colitis and Crohn's disease, declined.」
The company continues to report declines in sales of long-listed products such as Kipres and Pentasa as an impact following the expiration of patents on core products. - FY2022-Q2Increase in sales due to supply concerns affecting long-listed productsAnnual report
「Sales of long-listed products such as Pentasa, a treatment for ulcerative colitis and Crohn's disease, and Mucodyne, an airway mucus regulator and mucosal normalizer, increased as quality violations and administrative sanctions involving certain generic drug companies caused supply concerns for their products.」
While previous filings had described declines in long-listed products following the expiration of patents on core products, this filing explains that sales of some long-listed products increased due to supply concerns arising from quality problems and administrative sanctions involving other companies. - FY2021-Q3RestatedAnnual report
「Sales of long-listed products, including Kipres, a treatment for bronchial asthma and allergic rhinitis, and Mucodyne, an airway mucus regulator and mucosal normalizer, also declined,」
The company continues to report the decline in sales of long-listed products such as Kipres and Mucodyne as an impact following the expiration of patents on core products. - FY2021-Q2RestatedAnnual report
「Sales of long-listed products, including Kipres, a treatment for bronchial asthma and allergic rhinitis, and Mucodyne, an airway mucus regulator and mucosal normalizer, also declined,」
The company continues to report the decline in sales of long-listed products such as Kipres and Mucodyne as an impact following the expiration of patents on core products. - FY2021-Q1RestatedAnnual report
「Sales of long-listed products, including Kipres, a treatment for bronchial asthma and allergic rhinitis, and Mucodyne, an airway mucus regulator and mucosal normalizer, also declined,」
The decline in sales of long-listed products such as Kipres and Mucodyne continues to be reported as an impact following the expiration of patents on core products. - FY2020-Q1RestatedAnnual report
「Sales of long-listed products, including Kipres, a treatment for bronchial asthma and allergic rhinitis, and Mucodyne, an airway mucus regulator and mucosal normalizer, declined,」
The decline in sales of long-listed products such as Kipres continues as an impact following the expiration of patents on core products. - FY2019RestatedAnnual report
「Our group faced an unprecedented major change in its operating environment when patents on its core products expired in fiscal 2016.」
The company continues to explain that patents on core products expired in fiscal 2016 and that this was followed by a major change in the operating environment. - FY2018RestatedAnnual report
「Our group reached a critical stage requiring unprecedented corporate action, as the impact of patent expirations on core products on sales extended throughout the year.」
The company continues to explain the situation in which the impact of patent expirations on core products on sales extended throughout the year. - FY2018-Q3RestatedAnnual report
「Furthermore, our group reached a stage requiring unprecedented corporate action as the impact of patent expirations on core products on sales materialized in earnest.」
The company continues to explain the situation in which the impact of patent expirations on core products on sales has materialized in earnest. - FY2018-Q2RestatedAnnual report
「Our group reached a stage requiring unprecedented corporate action, as the impact of patent expirations on core products on sales began to materialize in earnest.」
The company continues to explain the situation in which the impact of patent expirations on core products on sales has materialized in earnest. - FY2018-Q1WorsenedAnnual report
「Our group reached a stage requiring unprecedented corporate action, as the impact of patent expirations on core products on sales began to materialize in earnest.」
The company explained that the impact on sales from patent expirations on core products had begun to materialize in earnest, making the previously observed impact more apparent. - FY2017MaterialisedAnnual report
「Sales of Kipres, a treatment for bronchial asthma and allergic rhinitis, declined following the expiration of its patent.」
The patent on Kipres actually expired, and the sales decline and response through the launch of an authorized generic were disclosed. - FY2017-Q3MaterialisedAnnual report
「Sales of Kipres, a treatment for bronchial asthma and allergic rhinitis, declined because its authorized generic was launched by our subsidiary キョーリン リメディオ㈱ in September 2016 in response to the patent expiration.」
The patent on the core product Kipres actually expired, and the response and impact, namely the launch of an authorized generic and the resulting sales decline, were explicitly stated. - FY2017-Q2First statedAnnual report
「We reached a point at which unprecedented corporate action was required, including in response to patent expiries for core products.」
The patent expiry of a core product emerged as a business risk requiring measures such as the launch of an authorized generic.